Nicole Drezner - Concepedia

Author

Nicole Drezner

United States Food and Drug Administration ORCID

Also Known As

N. Drezner, Nicole Drezner, Nicole L Drezner, Nicole L. Drezner, Nicole Lauren Drezner

Publications

963

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research

About

Nicole Drezner is an author at United States Food and Drug Administration specializing in radiation oncology, immune surveillance, and tumor immunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	102
2	Cancer Therapeutics	2	2	102
3	Health Sciences	1	1	48
4	Immunology	1	1	54
5	Pathology	1	1	48

Nicole Drezner

Publications

710

Citations

H-Index

Page 1

	Year	Citations
FDA Approval Summary: Sotorasib for <i>KRAS G12C</i> -Mutated Metastatic NSCLC Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, Clinical Cancer Research	2021	293
Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis. Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima, Journal of Clinical Oncology	2022	77
FDA Approval Summary: Dabrafenib in Combination with Trametinib for <i>BRAF</i>V600E Mutation–Positive Low-Grade Glioma Michael I. Barbato, Jeannette Nashed, Diana Bradford, Clinical Cancer Research	2023	59
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review Abigail L. Koch, Paz J. Vellanki, Nicole Drezner, Clinical Cancer Research	2021	58
Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. Erica C. Nakajima, Yi Ren, Jonathon Vallejo, Journal of Clinical Oncology Advanced NsclcPd-l1 ExpressionMedicineKras MutationNsclc Benefit	2022	54
Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis. Oladimeji Akinboro, Jonathon Vallejo, Pallavi S. Mishra‐Kalyani, Journal of Clinical Oncology Pd-l1-positive NsclcAdvanced NsclcChemotherapy Versus ImmunotherapyMedicineClinical Trials	2021	48
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer Oladimeji Akinboro, Nicole Drezner, Anup Amatya, Journal of Clinical Oncology	2023	37
FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations Elizabeth S. Duke, Liza Stapleford, Nicole Drezner, Clinical Cancer Research	2022	36
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials Jonathon Vallejo, Harpreet Singh, Erin Larkins, The Oncologist	2024	15
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer Michael I. Barbato, Diana Bradford, Yi Ren, Clinical Cancer Research	2024	11

Page 1